Highly sensitive system and method for analysis of troponin
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/53
G01N-033/68
G01N-021/64
G01N-033/58
출원번호
US-0798547
(2013-03-13)
등록번호
US-9182405
(2015-11-10)
발명자
/ 주소
Goix, Philippe
Puskas, Robert
Todd, John
Livingston, Richard
Held, Douglas
Wu, Allan H. B.
출원인 / 주소
Singulex, Inc.
대리인 / 주소
McDonnell Boehnen Hulbert & Berghoff LLP
인용정보
피인용 횟수 :
0인용 특허 :
137
초록
The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
대표청구항▼
1. A method for determining a characteristic of cardiovascular health, comprising: (a) determining a threshold concentration of at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) in blood, serum or plasma in a healthy population, wherein the threshold concentration is less than
1. A method for determining a characteristic of cardiovascular health, comprising: (a) determining a threshold concentration of at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) in blood, serum or plasma in a healthy population, wherein the threshold concentration is less than about 10 pg/ml;(b) measuring the concentration of the at least one of cTnI and cTnT in a blood, serum or plasma sample from the subject in a single molecule counting assay having a limit of detection for the at least one of cTnI and cTnT of less than 3 pg/mL and a coefficient of variation of less than 10%, wherein the assay comprises contacting the sample with an antibody specific for the at least one of cTnI and cTnT and determining the amount of specific binding between the antibody and the at least one of cTnI and cTnT,(c) determining a characteristic of cardiovascular health in the individual when the concentration of the at least one of cTnI and cTnT in the sample is greater than concentration of the at least one of cTnI and cTnT in the threshold concentration. 2. The method of claim 1, wherein the characteristic of cardiovascular health is at least one of acute myocardial infarction, risk of myocardial infarction, cardiac damage, progression of cardiac damage, cardiac toxicity, likelihood of a cardiac event, acute coronary syndrome, myocarditis, heart failure, and likelihood of heart failure. 3. The method of claim 1, wherein the threshold concentration is within the range of 1 pg/ml to 10 pg/ml. 4. The method of claim 1, wherein the threshold concentration is less than about 7 pg/ml. 5. The method of claim 1, wherein the threshold concentration is less than about 8 pg/ml. 6. The method of claim 1, wherein the threshold concentration is less than about 9 pg/ml. 7. The method of claim 1, wherein the sample is taken during a stress test. 8. The method of claim 1, wherein the sample is taken after a stress test. 9. The method of claim 1, wherein the assay detects a photon emission from a label corresponding to a single molecule of the at least one of cTnI and cTnT in the sample, wherein the at least one antibody is bound to or was bound to a molecule of the at least one of cTnI and cTnT in the sample. 10. The method of claim 9, wherein the antibody is eluted from the at least one of cTnI or cTnT before the photon emission is detected. 11. The method of claim 9, wherein the photon emission is detected in a single molecule analyzer. 12. The method of claim 1, wherein the assay is conducted using an analyzer comprising: (a) an electromagnetic radiation source for stimulating a fluorescent moiety; and(b) an electromagnetic radiation detector that measures an electromagnetic characteristic of the fluorescent moiety when stimulated by the electromagnetic radiation. 13. The method of claim 1 wherein step (b) further comprises assessing a non-troponin indicator in the sample, and step (c) comprises determining a characteristic of cardiovascular health based on the concentration of the at least of one the cTnI and cTnT and the assessment of the non-troponin indicator in said sample. 14. The method of claim 13, wherein the non-troponin indicator is at least one marker selected from the group consisting of creatine kinase (CK), myocardial fraction CK myocardial band (MB), aspartate aminotransferase, lactate dehydrogenase (LDH), α-hydroxybutyrate dehaydrogenase, myoglobin, glutamate oxaloacetate transaminase, glycogen phosphorylase BB, unbound free fatty acids, heart fatty acid binding protein (H-FABP), ischemia-modified albumin, myosin light chain 1, myosin light chain 2. 15. The method of claim 13, wherein the non-troponin indicator is at least one marker selected from the group consisting of C-reactive protein (CRP), white blood cell count, soluble CD40 ligand, myeloperoxidase, monocyte chernoattractant protein-1, whole blood choline, and pregnancy-associated plasma protein A. 16. The method of claim 13, wherein the non-troponin indicator is at least one marker selected from the group consisting of Interieukin 8, Interleukin 1β, Interleukin 6, Interleukin 10, Tumor Necrosis Factor, and Interleukin 12p70. 17. A method for determining a characteristic of cardiovascular health, comprising: (a) measuring the concentration of at least one of cTnI and cTnT in a series of samples blood, serum or plasma samples from the subject in a single molecule counting assay having a limit of detection for the at least one of cTnI and cTnT of less than 3 pg/mL and a coefficient of variation of less than 10%, wherein the assay comprises contacting the samples with an antibody specific for the at least one of cTnI and cTnT and determining the amount of specific binding between the antibody and the at least one of cTnI and cTnT,(b) determining a characteristic of cardiovascular health in the individual when the concentration of the at least one of cTnI and cTnT is increasing above a threshold concentration in the series samples, and wherein the threshold concentration is less than 10 pg/mL. 18. The method of claim 17, wherein the characteristic of cardiovascular health is at least one of acute myocardial infarction, risk of myocardial infarction, cardiac damage, progression of cardiac damage, cardiac toxicity, likelihood of a cardiac event, acute coronary syndrome, myocarditis, heart failure and likelihood of heart failure. 19. The method of claim 17, wherein the method is performed periodically over a period of up to about 30 hours on samples from the same patient taken at different times during the 30 hour period. 20. The method of claim 17, wherein an interval between samples is less than about 4 hours. 21. The method of claim 17 wherein a rate of change in the level of the at least one of the cTnI and cTnT between individual samples in the series of samples is detected. 22. The method of claim 17, wherein the threshold concentration represents the 99th percentile concentration of the at least one of cTnI and cTnT in a population of healthy individuals. 23. The method of claim 17, wherein the threshold concentration of cTnI is within the range of 1 pg/ml to 10 pg/ml. 24. The method of claim 17, wherein the threshold concentration is less than about 7 pg/ml. 25. The method of claim 17, wherein the threshold concentration is less than about 8 pg/ml. 26. The method of claim 17, wherein the threshold concentration is less than about 9 pg/ml. 27. The method of claim 17, wherein the assay detects a photon emission from a label corresponding to a single molecule of the at least one of cTnI and cTnT in the sample, wherein the antibody is bound to or was bound to a molecule of the at least one of cTnI and cTnT in the sample. 28. The method of claim 27, wherein the antibody is eluted from the at least one of cTnI or cTnT before the photon event. 29. The method of claim 27, wherein the photon emission is detected in a single molecule analyzer. 30. The method of claim 17, wherein the assay is conducted using an analyzer comprising: (a) an electromagnetic radiation source for stimulating a fluorescent moiety; and(b) an electromagnetic radiation detector that measures an electromagnetic characteristic of the fluorescent moiety when stimulated by the electromagnetic radiation. 31. The method of claim 17, wherein step (a) further comprises assessing a non-troponin indicator in at least one sample in the series of samples, and step (b) further comprises determining a characteristic of cardiovascular health based on the concentration of the at least of one the cTnI and cTnT and the assessment of the non-troponin indicator in the at least one said sample. 32. The method of claim 31, wherein the non-troponin indicator is at least one marker selected from the group consisting of creatine kinase (CK), myocardial fraction CK myocardial band (MB), aspartate aminotransferase, lactate dehydrogenase (LDH), α-hydroxybutyrate dehaydrogenase, myoglobin, glutamate oxaloacetate transaminase, glycogen phosphorylase BB, unbound free fatty acids, heart fatty acid binding protein (H-FABP), ischemia-modified albumin, myosin light chain 1, myosin light chain 2. 33. The method of claim 31, wherein the non-troponin indicator is at least one marker selected from the group consisting of C-reactive protein (CRP), white blood cell count, soluble CD40 ligand, myeloperoxidase, monocyte chemoattractant protein-1, whole blood choline, and pregnancy-associated plasma protein A. 34. The method of claim 31, wherein the non-troponin indicator is at least one marker selected from the group consisting of Interleukin 8, Interleukin 1β, Interleukin 6, Interleukin 10, Tumor Necrosis Factor, and Interleukin 12p70. 35. The method of claim 1, wherein the antibody is attached to a fluorescent moiety. 36. The method of claim 12, wherein electromagnetic radiation from the electromagnetic radiation source defines an interrogation space within a sample container and the detector measures the electromagnetic characteristic of the fluorescent moiety in the interrogation space. 37. The method of claim 17, wherein the antibody is attached to a fluorescent moiety. 38. The method of claim 30, wherein electromagnetic radiation from the electromagnetic radiation source defines an interrogation space within a sample container and the detector measures the electromagnetic characteristic of the fluorescent moiety in the interrogation space. 39. The method of claim 1, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 40. The method of claim 1, wherein h at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnT. 41. The method of claim 17, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 42. The method of claim 17, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnT.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (137)
Heller Michael J. (Encinitas CA) Tu Eugene (San Diego CA), Active programmable electronic devices for molecular biological analysis and diagnostics.
Chang, Richard K.; Pan, Young-Le; Pinnick, Ronald G.; Hill, Steven C., Aerosol fluorescence spectrum analyzer for rapid measurement of single airborne particles.
Crosby,Peter A.; Morris,Deborah L.; Soane,Mark M., Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin.
Baer Thomas M. (Mountain View CA) Dietz Louis J. (Mountain View CA) Dubrow Robert S. (San Carlos CA) Hayter Paul G. (Los Altos CA) Hodges Michael (Palo Alto CA) Manian Bala S. (Los Altos Hills CA) Sh, Apparatus and method for volumetric capillary cytometry.
Serena,Joaqu��n; Dāvalos,Antoni; Castellanos,Mar; Castillo,Jos��; Diamond,Cornelius Allen, Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof.
Chow Calvin Y. H. ; Parce John Wallace ; McReynolds Richard J. ; Kennedy Colin B. ; Bousse Luc J., Controller/detector interfaces for microfluidic systems.
Bergmann, Andreas; Morgenthaler, Nils; Papassotiriou, Jana; Struck, Joachim; Ng, Leong L., Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP.
Bergmann, Andreas; Morgenthaler, Nils; Papassotiriou, Jana; Struck, Joachim; Anker, Stefan, Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients.
Valkirs, Gunars E.; Dahlen, Jeffrey R.; Kirchick, Howard J.; Buechler, Kenneth F., Diagnostic markers of stroke and cerebral injury and methods of use thereof.
Hoffman Michael A. (Carmel CA), Fluorescent-particle analyzer with timing alignment for analog pulse subtraction of fluorescent pulses arising from diff.
Wada, H. Garrett; Kopf-Sill, Anne R.; Alajoki, Marja Liisa; Parce, J. Wallace; Wang, Benjamin N.; Chow, Andrea W.; Dubrow, Robert S., Focusing of microparticles in microfluidic systems.
Swedberg Sally A. (Los Altos CA) Kaltenbach Patrick (Bischweier DEX) Witt Klaus E. (Keltern DEX) Bek Fritz (Waldbronn DEX) Mittelstadt Laurie S. (Belmont CA), Fully integrated miniaturized planar liquid sample handling and analysis device.
Dollinger Gavin D. (San Francisco CA) Cunico Robert L. (Hercules CA) Kunitani Michael G. (San Rafael CA), HPLC light scattering detector for biopolymers.
Mathies Richard A. (Contra Costa County CA) Peck Konan (Contra Costa County CA) Stryer Lubert (Santa Clara County CA), High sensitivity fluorescent single particle and single molecule detection apparatus and method.
Ambrose W. Patrick ; Grace W. Kevin ; Goodwin Peter M. ; Jett James H. ; Orden Alan Van ; Keller Richard A., High throughput analysis of samples in flowing liquid.
Goix, Philippe; Puskas, Robert; Todd, John; Livingston, Richard; Held, Douglas; Wu, Allan H. B., Highly sensitive system and method for analysis of troponin.
Bergmann, Andreas; Ernst, Andrea; Hampel, Harald, In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative disorders.
Witt Klaus E. (Keltern DEX) Kaltenbach Patrick (Bischweier DEX) Bek Fritz (Waldbronn DEX) Swedberg Sally A. (Los Altos CA) Mittelstadt Laurie S. (Belmont CA), Low voltage miniaturized column analytical apparatus and method.
Begg Geoffrey Stephen (Heidelberg AUX) Simpson Richard John (Richmond AUX) Burgess Antony Wilks (Camberwell AUX), Method allowing sequential chemical reactions.
Purvis ; Jr. Norman B. (1010 Lawnview Ct. Franklin TN 37064) Giorgio Todd D. (3608 Westbrook Dr. Nashville TN 37205), Method and apparatus for determining absolute particle size, surface area and volume normalized fluorescence using forwa.
Cherukuri Satyam C. (Cranbury NJ) Demers Robert R. (Cranbury NJ) Fan Zhong H. (Middlesex NJ) Levine Aaron W. (Lawrenceville NJ) McBride Sterling E. (Lawrence Township ; Mercer County NJ) Zanzucchi Pe, Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device.
Bergmann, Andreas, Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides.
Bergmann, Andreas; Papassotiriou, Jana; Struck, Joachim; Morgenthaler, Nils; Anker, Stefan, Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease.
Seidel Claus,DEX ; Gunther Rolf,DEX ; Lupke Stefan,DEX, Method for differentiating or detecting particles in a sample by identifying signal segments of time-resolved, optical raw signals from the sample on the basis of single photon detection.
Goix, Philippe J.; Puskas, Robert; Todd, John; Livingston, Richard A.; Held, Douglas, Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties.
Bergmann, Andreas; Struck, Joachim, Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method.
Bergmann, Andreas; Struck, Joachim, Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method.
Robotti, Karla M.; Yin, Hongfeng, Methods and using chemico-mechanical microvalve devices for the selective separation of components from multi-component fluid samples.
Buechler,Kenneth F.; McPherson,Paul H., Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays.
Bergmann, Andreas; Struck, Joachim; Morgenthaler, Nils G., Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists.
Kaltenbach Patrick,DEX ; Swedberg Sally A. ; Witt Klaus E.,DEX ; Bek Fritz,DEX ; Mittelstadt Laurie S., Miniaturized planar columns for use in a liquid phase separation apparatus.
Kaltenbach Patrick (Bischweier DEX) Swedberg Sally A. (Los Altos CA) Witt Klaus E. (Keltern DEX) Bek Fritz (Waldbronn DEX) Mittelstadt Laurie S. (Belmont CA), Miniaturized planar columns in novel support media for liquid phase analysis.
Bottomley Paul A. (Clifton Park NY) Edelstein William A. (Schenectady NY), NMR Imaging of the transverse relaxation time using multiple spin echo sequences.
Hollis Mark A. (Concord MA) Ehrlich Daniel J. (Lexington MA) Murphy R. Allen (Boxboro MA) Kosicki Bernard B. (Acton MA) Rathman Dennis D. (Ashland MA) Chen Chang-Lee (Sudbury MA) Mathews Richard H. (, Optical and electrical methods and apparatus for molecule detection.
Goodwin Peter M. ; Jett James H. ; Keller Richard A. ; Van Orden Alan K. ; Machara Nicholas P., Single molecule identification using selected fluorescence characteristics.
Galambos, Paul C.; Okandan, Murat; Montague, Stephen; Smith, James H.; Paul, Phillip H.; Krygowski, Thomas W.; Allen, James J.; Nichols, Christopher A.; Jakubczak, II, Jerome F., Surface-micromachined microfluidic devices.
Doth Margit,DEX ; Petry Christoph,DEX, Synthetic calibrators for use in immunoassays, comprising the analytes or partial sequences thereof which are conjugated to inert carrier molecules.
Myers Stephen A. (25 Nimitz Pl. Old Greenwich CT 06870), System and method for determining changes in fluorescence of stained nucleic acid in electrophoretically separated bands.
Muller Ralph,DEX ; Sauer Markus,DEX ; Zander Christoph,DEX, System for distinguishing fluorescent molecule groups by time resolved fluorescence measurement.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.